During the pandemic, a waiver was issued that allowed telehealth companies to prescribe controlled substances such as buprenorphine to patients without seeing them for an in-person consultation.
But, the Biden administration is now proposing a rule that will discontinue the ability for telemedicine prescribing of controlled substances where the patient has never had an in-person consultation.
Specifically, under the new rule, patients could receive a 30-day supply of buprenorphine without an in-person exam, but would then need an in-person consultation to continue to receive prescriptions via telehealth.
The DEA is expected to release a draft of the new rule following its comment period.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
